explore -WSS

explore

author：knowledge 2025-10-06 07:43:45 - browse：262

Novo Nordisk headquarters -- health coverage from STAT — Novo Nordisk's headquarters, outside Copenhagen, Denmark. LISELOTTE SABROE/Scanpix/AFP via Getty Images

Novo Nordisk is pausing ads for its obesity drug Wegovy as it struggles to keep up with surging demand, the latest hurdle in its rollout of the weight loss drug.

“To avoid stimulating further demand for this medicine, we’re pausing some key Wegovy promotional efforts,” the Danish drugmaker said in an emailed statement. “We are pausing all local television advertising and postponing planned national television advertising for Wegovy. We are also assessing our promotional efforts to healthcare professionals and adjusting accordingly.” The news was earlier reported by Endpoints.

Wegovy, which contains the active ingredient semaglutide, has become immensely popular for its effectiveness in helping people lose weight and is helping usher in what many see as a sea change in obesity treatment. Its sister drug for diabetes, Ozempic, has also been in demand for a similar effect on weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Latest bird flu infection made farmworker sicker than earlier cases

WSS

Startling documents reveal new facets of Sacklers' opioid empire

Heat waves linked to early deliveries, preterm births in new study

Dark money group runs ads on China biotech bill

Akili, maker of video game for ADHD, to be acquired for 34 million

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

focus

explore

entertainment

23andMe had bad news about my health. I wish a person had delivered it

In age of alternative facts, a scholarly course on calling out crap

ChatGPT in medicine: STAT answers readers' burning questions

Alkermes shareholders re

Duchenne breakthrough therapy leaves behind pioneering families

After affirmative action ruling, medical educators look to 'holistic review'

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Trump demands the U.S. pay no more for drugs than other countries … again

State Dept. review finds Biden bears some blame for Afghanistan failures

How to save PrEP access — and even expand it

hotspot

Drug repurposing or repositioning? The language matters

David Sabatini, ex

At least 13 dead in Texas as scorching temps continue

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

ChatGPT in medicine: STAT answers readers' burning questions

DIEP, the 'gold standard' of breast reconstruction, is under threat

Wikipedia

focus

leisure time

entertainment